Spero Therapeutics, Inc. Forecasted to Post Q1 2024 Earnings of ($0.37) Per Share (NASDAQ:SPRO)

Posted by on Apr 12th, 2023

Spero Therapeutics, Inc. (NASDAQ:SPRO – Get Rating) – Analysts at HC Wainwright issued their Q1 2024 earnings estimates for shares of Spero Therapeutics in a research report issued to clients and investors on Monday, April 10th. HC Wainwright analyst R. Selvaraju anticipates that the company will post earnings of ($0.37) per share for the quarter. HC Wainwright has a “Buy” rating and a $6.00 price target on the stock. The consensus estimate for Spero Therapeutics’ current full-year earnings is ($1.13) per share. HC Wainwright also issued estimates for Spero Therapeutics’ Q2 2024 earnings at ($0.39) EPS, Q3 2024 earnings at ($0.39) EPS and Q4 2024 earnings at $0.59 EPS.

Separately, Cantor Fitzgerald reissued an “overweight” rating on shares of Spero Therapeutics in a research report on Friday, March 31st. Two research analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $6.33.

Spero Therapeutics Price Performance

Shares of NASDAQ:SPRO opened at $1.62 on Tuesday. The firm has a market capitalization of $85.16 million, a PE ratio of -0.98 and a beta of 0.88. The firm’s 50-day moving average is $1.58 and its two-hundred day moving average is $1.77. Spero Therapeutics has a 1 year low of $0.68 and a 1 year high of $7.01.

Hedge Funds Weigh In On Spero Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in SPRO. Dimensional Fund Advisors LP grew its position in shares of Spero Therapeutics by 9.6% during the first quarter. Dimensional Fund Advisors LP now owns 406,946 shares of the company’s stock worth $3,540,000 after buying an additional 35,724 shares in the last quarter. Vanguard Group Inc. boosted its holdings in Spero Therapeutics by 1.7% in the first quarter. Vanguard Group Inc. now owns 1,373,928 shares of the company’s stock valued at $11,953,000 after purchasing an additional 22,550 shares in the last quarter. XTX Topco Ltd acquired a new position in Spero Therapeutics in the first quarter valued at approximately $115,000. Renaissance Technologies LLC acquired a new position in Spero Therapeutics in the first quarter valued at approximately $949,000. Finally, Engineers Gate Manager LP acquired a new position in Spero Therapeutics in the first quarter valued at approximately $95,000. 57.38% of the stock is owned by institutional investors and hedge funds.

Spero Therapeutics Company Profile

(Get Rating)

Spero Therapeutics, Inc is a clinical-stage biopharmaceutical company, which focuses on identifying, developing, and commercializing treatments involving bacterial infections, including multi-drug resistant bacterial infections, and rare diseases Its pipeline product candidates include Tebipenem HBr, SPR720, and SPR206.

Read More

Receive News & Ratings for Spero Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spero Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.